News

Public · Published

NH: Q2 revenue was ₹28,439.89m; continuing-operations net profit was ₹3,011.53m

Q2 consolidated revenue reached ₹28,439.89m and EBITDA ₹6,054.15m, with continuing-operations net profit of ₹3,011.53m. Insurance and medical services segment results diverged, while pending merger and demerger approvals remain key developments.

Published:

Updated:

What happened

Q2 consolidated revenue reached ₹28,439.89m and EBITDA ₹6,054.15m, with continuing-operations net profit of ₹3,011.53m. Insurance and medical services segment results diverged, while pending merger and demerger approvals remain key developments.

Confirmed

Global impact / market context

Revenue and profit show the core hospital business is still generating earnings, but diverging insurance and medical services results mean profit quality depends on which segment drives growth. Pending merger and demerger approvals add uncertainty about future corporate structure and how assets are grouped.

Analyst inference

Investors are weighing steady headline revenue against uneven segment performance, so attention shifts to the mix of earnings rather than the total. Approvals for the merger and demerger are a structural catalyst, which means investor positioning may hinge on clarity about the final corporate shape.

Analyst inference

What to watch

  1. Pending merger and demerger approvals remain key developments that could change how the company's businesses are grouped and reported to investors. Confirmed
  2. Watch whether the company provides more detail on the merger and demerger timeline, since clarity on approvals would reduce uncertainty about the future corporate structure. Proposed
  3. Track the gap between insurance and medical services segment results, because continued divergence would affect where profit comes from and how durable earnings appear. Analyst inference

Evidence

  • Original source link unavailable